Morgan Stanley: CSPC Pharma Keeps "Overweight" Rating with HK$12 Target Price

Deep News11-20 10:30

Morgan Stanley has released a research report stating that CSPC Pharma (01093) reported third-quarter finished drug sales slightly above expectations, with multiple pipeline catalysts ahead that reinforce the bank's investment thesis. The bank maintains its "Overweight" rating on CSPC Pharma with a target price of HK$12.

Morgan Stanley noted that the company aims to maintain positive growth in finished drug sales through 2027, with no price cut for NBP (under national centralized procurement), while Mingfule will see a roughly 9% price reduction under the national medical insurance catalog, and the company has more than 10 innovative drugs in total. Third-quarter finished drug sales rose 10% year-on-year and 2.5% quarter-on-quarter, with central nervous system (CNS) drugs up 32% year-on-year, oncology drugs down 23%, anti-infective drugs up 2%, cardiovascular drugs down 15%, respiratory drugs down 15%, digestive drugs up 41%, and other drugs down 2%. Third-quarter business development revenue reached RMB 373 million, while business development revenue for the first nine months of 2026 totaled RMB 6.3 billion, including partial upfront payments and milestones from the AstraZeneca long-acting peptide platform and the Nectin-4 ADC.

Third-quarter gross margin rose 1 percentage point year-on-year to 67%, the selling and administrative expense ratio for finished drug sales fell 6 percentage points, the R&D ratio remained broadly stable at 31%, and third-quarter adjusted net profit grew 39% year-on-year. The bank noted that upcoming catalysts include Phase III readouts for the EGFR ADC in second-line EGFR-mutant non-small cell lung cancer, to be presented at the ESMO Asia conference in early December, as well as early durability data and potential globalization updates for PD-1/IL-15 in 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment